MY161396A - Benzoic acid salt of otamixaban - Google Patents
Benzoic acid salt of otamixabanInfo
- Publication number
- MY161396A MY161396A MYPI2013003459A MYPI2013003459A MY161396A MY 161396 A MY161396 A MY 161396A MY PI2013003459 A MYPI2013003459 A MY PI2013003459A MY PI2013003459 A MYPI2013003459 A MY PI2013003459A MY 161396 A MY161396 A MY 161396A
- Authority
- MY
- Malaysia
- Prior art keywords
- benzoic acid
- acid salt
- amino
- methyl
- otamixaban
- Prior art date
Links
- PFGVNLZDWRZPJW-OPAMFIHVSA-N otamixaban Chemical compound C([C@@H](C(=O)OC)[C@@H](C)NC(=O)C=1C=CC(=CC=1)C=1C=C[N+]([O-])=CC=1)C1=CC=CC(C(N)=N)=C1 PFGVNLZDWRZPJW-OPAMFIHVSA-N 0.000 title abstract 2
- 150000001558 benzoic acid derivatives Chemical class 0.000 title 1
- 229950009478 otamixaban Drugs 0.000 title 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical class OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 abstract 1
- 108010074860 Factor Xa Proteins 0.000 abstract 1
- 101000740162 Homo sapiens Sodium- and chloride-dependent transporter XTRP3 Proteins 0.000 abstract 1
- -1 IMINO Chemical class 0.000 abstract 1
- 102100037189 Sodium- and chloride-dependent transporter XTRP3 Human genes 0.000 abstract 1
- 230000001668 ameliorated effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11305348 | 2011-03-29 | ||
| US201161500342P | 2011-06-23 | 2011-06-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY161396A true MY161396A (en) | 2017-04-14 |
Family
ID=44065390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2013003459A MY161396A (en) | 2011-03-29 | 2012-03-27 | Benzoic acid salt of otamixaban |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8993602B2 (enExample) |
| EP (1) | EP2691371B1 (enExample) |
| JP (1) | JP5959617B2 (enExample) |
| KR (1) | KR101852226B1 (enExample) |
| CN (1) | CN103562183B (enExample) |
| AU (1) | AU2012234325B2 (enExample) |
| BR (1) | BR112013025105A2 (enExample) |
| CA (1) | CA2830965C (enExample) |
| CY (1) | CY1116659T1 (enExample) |
| DK (1) | DK2691371T3 (enExample) |
| ES (1) | ES2539236T3 (enExample) |
| HR (1) | HRP20150613T1 (enExample) |
| IL (1) | IL228574A (enExample) |
| MX (1) | MX2013011266A (enExample) |
| MY (1) | MY161396A (enExample) |
| PL (1) | PL2691371T3 (enExample) |
| PT (1) | PT2691371E (enExample) |
| RU (1) | RU2597423C2 (enExample) |
| SG (1) | SG193612A1 (enExample) |
| SI (1) | SI2691371T1 (enExample) |
| WO (1) | WO2012130821A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG193932A1 (en) | 2011-03-29 | 2013-11-29 | Sanofi Sa | Otamixaban formulations with improved stability |
| CN106565698B (zh) * | 2016-08-15 | 2019-03-08 | 南京帕隆材料科技有限公司 | 取代噻唑类衍生物及其制备方法和用途 |
| CN106518859B (zh) * | 2016-08-15 | 2019-01-18 | 南京帕隆材料科技有限公司 | 噻唑类衍生物及其制备方法和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5424334A (en) | 1991-12-19 | 1995-06-13 | G. D. Searle & Co. | Peptide mimetic compounds useful as platelet aggregation inhibitors |
| US6080767A (en) * | 1996-01-02 | 2000-06-27 | Aventis Pharmaceuticals Products Inc. | Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides |
| IL125163A0 (en) * | 1996-01-02 | 1999-01-26 | Rhone Poulenc Rorer Pharma | Substituted n-[(aminoiminomethyl or aminomethyl) phenyl] propyl amides |
| GB0108903D0 (en) * | 2000-10-05 | 2001-05-30 | Aventis Pharm Prod Inc | Novel crystalline forms of a factor Xa inhibitor |
| KR101509829B1 (ko) * | 2007-05-02 | 2015-04-06 | 포톨라 파마슈티컬스, 인코포레이티드 | 혈소판 ａｄｐ 수용체 억제제로 작용하는 화합물을 이용한 병용요법 |
| BR112012001900A2 (pt) * | 2009-07-29 | 2016-03-15 | Sanofi Sa | otamixabano para tratamento de pacientes idosos com insuficiência renal e infarto do miocárdio sem elevação do st |
-
2012
- 2012-03-27 RU RU2013148005/04A patent/RU2597423C2/ru not_active IP Right Cessation
- 2012-03-27 JP JP2014501569A patent/JP5959617B2/ja active Active
- 2012-03-27 CN CN201280026534.0A patent/CN103562183B/zh active Active
- 2012-03-27 US US14/008,332 patent/US8993602B2/en active Active
- 2012-03-27 MY MYPI2013003459A patent/MY161396A/en unknown
- 2012-03-27 PT PT127118586T patent/PT2691371E/pt unknown
- 2012-03-27 CA CA2830965A patent/CA2830965C/en not_active Expired - Fee Related
- 2012-03-27 SI SI201230219T patent/SI2691371T1/sl unknown
- 2012-03-27 MX MX2013011266A patent/MX2013011266A/es active IP Right Grant
- 2012-03-27 SG SG2013071766A patent/SG193612A1/en unknown
- 2012-03-27 PL PL12711858T patent/PL2691371T3/pl unknown
- 2012-03-27 WO PCT/EP2012/055364 patent/WO2012130821A1/en not_active Ceased
- 2012-03-27 BR BR112013025105A patent/BR112013025105A2/pt not_active Application Discontinuation
- 2012-03-27 AU AU2012234325A patent/AU2012234325B2/en not_active Ceased
- 2012-03-27 KR KR1020137028416A patent/KR101852226B1/ko not_active Expired - Fee Related
- 2012-03-27 DK DK12711858.6T patent/DK2691371T3/da active
- 2012-03-27 ES ES12711858.6T patent/ES2539236T3/es active Active
- 2012-03-27 HR HRP20150613TT patent/HRP20150613T1/hr unknown
- 2012-03-27 EP EP12711858.6A patent/EP2691371B1/en active Active
-
2013
- 2013-09-29 IL IL228574A patent/IL228574A/en active IP Right Grant
-
2015
- 2015-06-17 CY CY20151100521T patent/CY1116659T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG193612A1 (en) | 2013-11-29 |
| PT2691371E (pt) | 2015-07-20 |
| US20140024684A1 (en) | 2014-01-23 |
| KR101852226B1 (ko) | 2018-04-25 |
| ES2539236T3 (es) | 2015-06-29 |
| MX2013011266A (es) | 2014-03-27 |
| EP2691371B1 (en) | 2015-03-18 |
| CN103562183A (zh) | 2014-02-05 |
| RU2013148005A (ru) | 2015-05-10 |
| HRP20150613T1 (hr) | 2015-07-17 |
| IL228574A (en) | 2015-07-30 |
| BR112013025105A2 (pt) | 2017-06-06 |
| JP5959617B2 (ja) | 2016-08-02 |
| KR20140022851A (ko) | 2014-02-25 |
| CA2830965A1 (en) | 2012-10-04 |
| DK2691371T3 (da) | 2015-06-22 |
| SI2691371T1 (sl) | 2015-07-31 |
| HK1189584A1 (en) | 2014-06-13 |
| AU2012234325A1 (en) | 2013-10-17 |
| AU2012234325B2 (en) | 2016-08-11 |
| CN103562183B (zh) | 2015-12-23 |
| WO2012130821A1 (en) | 2012-10-04 |
| CA2830965C (en) | 2019-04-09 |
| CY1116659T1 (el) | 2017-03-15 |
| PL2691371T3 (pl) | 2015-08-31 |
| IL228574A0 (en) | 2013-12-31 |
| EP2691371A1 (en) | 2014-02-05 |
| US8993602B2 (en) | 2015-03-31 |
| JP2014509622A (ja) | 2014-04-21 |
| RU2597423C2 (ru) | 2016-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2014028589A3 (en) | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| PH12013500301A1 (en) | Oxadiazole inhibitors of leukotriene production | |
| IN2015DN02573A (enExample) | ||
| EA201390934A1 (ru) | Композиции и способы модулирования fxr | |
| MX2015008187A (es) | Inhibidores de alk deuterados. | |
| MX2013005533A (es) | Derivados de acido amino-bisfenil-pentanoico sustituidos como inhibidores de nep. | |
| EA201370166A1 (ru) | Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы | |
| MX347616B (es) | Inhibidores de csf-1r para el tratamiento de tumores de cerebro. | |
| GEP20186880B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| PH12014502567A1 (en) | Piperidine derivatives for gpr119 agonist | |
| MX344109B (es) | Formulaciones de sal de meglumina del ácido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxílico. | |
| PH12013500411A1 (en) | Treatment of myocardial infarction using tgf - beta antagonists | |
| MX350862B (es) | Acidos de piperidinil naftilacetico. | |
| PH12013501991A1 (en) | Otamixaban formulations with improved stability | |
| EA201490928A1 (ru) | Способы лечения острых приступов подагры | |
| WO2009126861A3 (en) | Triazolopyridine compounds useful as dgat1 inhibitors | |
| PH12013500545A1 (en) | Oxadiazole inhibitors of leukotriene production | |
| MX2013011266A (es) | Sal de acido benzoico de otamixaban. | |
| WO2013117503A3 (en) | Pi3k inhibitors for treating fibrotic diseases | |
| WO2012112841A3 (en) | [1,2,4]oxadiazol-3-yl acid salts and crystalline forms and their preparation | |
| EP2772481A8 (en) | Novel compound as kcnq potassium channel agonist, preparation method therefor and use thereof | |
| MX2015010434A (es) | Derivados de acido bisfenil-butanoico sustituido como inhibidores de la endopeptidasa neutra (nep), con una mayor eficacia in vivo. | |
| MY162945A (en) | Azole derivative | |
| WO2012172427A3 (en) | Peptide compounds for inhibition of platelet aggregation | |
| WO2012025762A3 (en) | Pure intermediate for preparing letrozole |